Company Profile
Cardiff Oncology Stock Price, News & Analysis
Company overview
Business overview
Cardiff Oncology is an oncology-focused biopharmaceutical company centered on cancer programs, with investors watching clinical data, regulatory milestones, and the commercial path for its lead assets.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Cardiff Oncology is followed within the oncology universe where readouts and regulatory timing often dominate the stock.
Business Model Characteristics
Cardiff Oncology follows a pipeline-and-commercial model where investors track trial execution, launch cadence, and the pace at which oncology data can be turned into durable product value.
Position Within the Biotechnology Landscape
Compared with larger diversified peers, Cardiff Oncology sits in a high-catalyst corner of the biotech landscape, where oncology updates can reprice the stock quickly.
Why the stock is moving
CRDF is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Cardiff Oncology’s catalysts are onvansertib and the KRAS-driven oncology program, especially any new combination or clinical data that keep the story alive. The company remains highly dependent on proof of differentiation.
Recent news
The five most recent feed items are shown below in reverse chronological order.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.